BPC-157Recovery
Preclinical onlyNot approved for human use
Tissue repair across tendon, ligament and gut models.
One page per compound. Each carries an evidence tier, a regulatory status, and a plain account of what the human data actually covers — which is often not the use people buy it for. Figures appear only where there is a real personal reference behind them.
22 compounds
Tissue repair across tendon, ligament and gut models.
The research form of thymosin β-4 — wound healing, blood-vessel formation and tissue remodelling.
A four-peptide blend — GHK-Cu, BPC-157, TB-500 and KPV — combining skin, tissue-repair and anti-inflammatory signalling in a single draw.
GLP-1 receptor agonist.
Investigational triple agonist — GLP-1, GIP and glucagon receptors at once.
Tirzepatide is a dual GIP and GLP-1 receptor agonist, well established in large clinical trials and sold as a prescription product.
A peptide encoded inside mitochondrial DNA, studied as an exercise-mimetic signal tied to energy use and insulin sensitivity.
A coenzyme central to cellular energy and DNA repair.
Derived from ACTH; developed in Russia and used there in neurology.
A stabilised GHRH analogue.
Collagen and elastin synthesis, skin firmness, tissue regeneration.
The active C-terminal fragment of α-MSH — anti-inflammatory signalling across gut, skin and immune tissue.
A GHRH analogue plus a selective ghrelin-receptor agonist, studied together for a fuller natural GH pulse.
A selective ghrelin-receptor agonist and GH secretagogue — the same peptide in the CJC-1295 blend, but also used alone.
A GHRH analogue and one of the longest-standing tools in growth-hormone research.
A four-amino-acid peptide from Russian gerontology, proposed to activate telomerase.
Also called elamipretide.
Based on the immune fragment tuftsin; developed in Russia as an anxiolytic.
Delta sleep-inducing peptide — studied for deep delta-wave sleep activity.
A melanocortin agonist working through the nervous system rather than blood flow.
A melanocortin agonist that signals the skin to produce more melanin from less UV exposure.
A long-acting IGF-1 analogue — the growth factor downstream of growth hormone.
No compounds match that combination.
Evidence tier describes what kind of human data exists for the use discussed — not how well a compound works. Regulatory status is separate: a compound can be approved somewhere for one narrow indication and still have no evidence behind the use it is bought for. Nothing here is medical advice.